Myriad Genetics and Flatiron Health Collaborate to Expand Access to Genetic Testing Through EMR Integration

QIAGEN and Illumina Unveil New Solutions to Advance Liquid Biopsy and Next-Generation Sequencing

The Role of Biobanks in Advancing Precision Medicine

AstraZeneca and Daiichi Sankyo's Enhertu Secures Conditional Approval in China for HER2-Mutated NSCLC Treatment

SkylineDx Presents Breakthrough Data from Largest Melanoma Genomic Assay Trial at SMR Annual Meeting

Clario and PathAI Join Forces to Streamline GI Clinical Trials with Integrated Solutions

FDA Approves FoundationOne® Liquid CDx as Companion Diagnostic for Itovebi™ (inavolisib) to Identify Hormone Receptor-Positive, HER2-Negative Breast Cancer Patients with PIK3CA Mutation

Roche’s VENTANA CLDN18 (43-14A) RxDx Assay for Identifying Gastric and GEJ Cancer Patients Receives CE Mark Approval

Tempest and Roche Partner to Advance Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Singapore to Expand MediShield Life Coverage for Precision Medicine and Strengthen Genetic Data Protections

Bayer and MOMA Therapeutics Partner to Advance Precision Oncology Therapies

DermTech's Non-Invasive Genomic Testing Shows Promise in Differentiating Melanoma from Atypical Moles

Velsera and Diagnostic Longwood Partner to Accelerate Precision Medicine in Spain and Portugal

Aurigene Oncology Reports Promising Phase 1 Results for India’s First CAR-T Cell Therapy in Multiple Myeloma

Agilus Diagnostics Launches Pharmacogenomics Testing Service to Revolutionize Personalized Medicine

Home
/
update
/
details

Unveiling the Future of Cancer Care: Join Diaceutics' Virtual Event on Precision Medicine in Oncology

NextEdge Admin

11 Jun 2024

2 min 2 sec

Diaceutics announces its virtual event, "Precision Medicine in Oncology," on June 19, 2024. This event will feature eight live webinars followed by immersive virtual experiences, taking participants to the forefront of cancer testing and treatment.

Expert speakers include:

- Prof. Dr. Klaus Pantel, presenting "Implementation of Liquid Biopsy in Precision Oncology," offering insights into the evolution and application of liquid biopsy.

- Dr. Bob Holt, discussing "MRD in Solid Tumor & Hematological Indications," followed by Prof. Maria Teresa Voso, delving into MRD in AML.

- Prof. Paul Hoffman, exploring "New Challenges in Early-Stage Cancer," focusing on early detection and management.

- Dr. Clare Turnbull and Dr. Nicola Normanno, presenting "The Role of Comprehensive Genomic Profiling in Precision Oncology," addressing implications of large NGS panels.

- Prof. Sophie Prévot, discussing "Integrating AI in Pathology," showcasing AI's role in diagnoses and workflow efficiency.

Ryan Keeling, CEO of Diaceutics, emphasized their commitment to advancing cancer treatment through precision medicine, providing a platform for experts to share innovative practices and shape the future of oncology diagnostics.

The event targets laboratory professionals, pathologists, and stakeholders in oncology diagnostics and treatment. Attendees can engage in interactive sessions, visit the poster hall, and participate in real-time Q&A sessions with expert speakers.